Asahi Kasei Pharma Corporation

We believe great science comes from working together.

Asahi Kasei Pharma Corporation is focused on the discovery and development of new drugs that address unmet medical needs.

February 21, 2019: Maruho and Asahi Kasei Pharma Announce First Approval in Japan of an Additional Dosage and Administration for Anti-herpes Virus Agent "Famvir® Tab 250 mg" for the Treatment of Recurrent Herpes Simplex (Herpes labialis/Herpes genitalis)
January 28, 2019: Asahi Kasei Pharma launching legionella kit Ribotest™ Legionella
December 17, 2018: Asahi Kasei Pharma to solicit proposals for drug discovery research
December 11, 2018: Asahi Kasei Pharma launches Kevzara® autoinjector for treatment of rheumatoid arthritis
December 3, 2018: Addition of Kevzara® to category of drugs subject to guidance and management fee for self-injection at home and lift of ban on long-term prescription
October 30, 2018: Application for approval to manufacture and sell Teribone™ autoinjector
August 2, 2018: Preliminary results of overseas Phase III clinical study for ART-123
July 24, 2018: Asahi Kasei Pharma signs distribution agreement with Stanbio Laboratory for the marketing of Lucica® Glycated Albumin-L in the US

Page Top